Compare BioNano Genomics Inc (BNGO) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs F5 Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while F5 Inc trades at $417.74 (market cap $23.44B). The key difference: F5 Inc is far larger — about 1716× BioNano Genomics Inc's market cap, and F5 Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FFIV | |
|---|---|---|
Market Cap | $13.66M | $23.44B |
Sector | Health | Technology |
52-Week High | $4.92 | $431.26 |
52-Week Low | $1.06 | $223.99 |
Enterprise Value | $16.26M | $22.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
F5 (FFIV) stock trades at $417.70, up 1.88% with bullish technical signals and strong earnings beats. Recent Q3 2026 results showed EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. The company raised its fiscal outlook, reflecting robust demand for application security and AI infrastructure. Key support lies at $411, with resistance at $422.
Outlook remains positive due to consistent earnings outperformance and raised guidance, though valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus price target of $430.43 implies moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
